Navigation Links
Genetic Tests in the Treatment of Depression Not Yet Useful

rom all symptoms of depression after 1 year of treatment is approximately 40 percent, and side effects cause 12 percent to 15 percent of people who start treatment to stop taking the drug. Following the recent FDA approval of a test to predict differences in the CYP450 gene, clinicians and patients must decide whether using such tests to choose a type or dose of an SSRI might improve the patient's response to treatment.

In early 2007, the EGAPP working group, an independent, non-federal panel that advises the CDC, will issue recommendations on the use of CYP450 tests in the treatment of depression based on the evidence report and other considerations, including alternative approaches for dosing and monitoring of drug therapy, patient access to testing, and cost. The working group will also assess current knowledge gaps and describe additional research needs identified by the report. Future evidence reports that are part of the AHRQ/CDC collaboration will evaluate the use of genomic tests for specific diseases or conditions, such as a rare type of inherited colorectal cancer.

Source-NewswiseSRM
'"/>




Page: 1 2 3

Related medicine news :

1. Genetic Dentistry: Your Dentist may be able to grow you a new set of Teeth.
2. Genetic influence in menopause
3. Genetics and cholesterol levels
4. Genetics helps in attacking cancer
5. Genetic disorder related with sleep patterns
6. Genetic innovation
7. Genetic tests for cancer
8. Genetic indicates memory
9. Genetic mutation to the fountain of youth discovered
10. Genetic differences found between Male and Female brains
11. Alcoholism Influenced By Both Genetics & Family Environment
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genetic Tests the Treatment Depression Not Yet Useful

(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Tomas Ganz, MD, ... with the 2014 E. Donnall Thomas Lecture for his ... the iron-regulatory hormone hepcidin and investigation of its roles ... Prize Laureate and past Society president E. Donnall Thomas, ... represented a paradigm shift or significant discovery in the ...
(Date:7/22/2014)... at the University of Utah,s John A. Moran Eye ... Eye Research (ISER) as the recipient of the Houston, ... in Retina Research., The award recognizes lifetime achievement by ... to the understanding of vitreoretinal diseases or disorders. The ... Biennial Meeting in San Francisco, where Marc will deliver ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC News, ... favorite beauty products, “ Botox , that’s pretty much it.” ... has changed my life” by halving the amount of ... various, daily appearances. “Suddenly my eyelids are no longer ... “I think that Kelly Ripa’s response to the question was ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)... , July 22, 2014 WuXi PharmaTech (Cayman) ... and medical device R&D outsourcing company with operations in ... , today announced that it will release financial results ... Stock Exchange closes on Wednesday, August 13, 2014 (which will ... release will be available on the investor relations section of ...
(Date:7/22/2014)... July 22, 2014  UL (Underwriters Laboratories), a ... U.S. Food and Drug Administration (FDA) has recognized ... for medical devices incorporating lithium or nickel-based batteries. ... for Household and Commercial Batteries, and UL 1642 ... Consensus standards are standards recognized by the ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... 6, 2011 A new study , released ... the United States witnessed opiate prescriptions for chronic abdominal ... Michael Lowenstein, co-medical director for the Waismann Method, an ... that this increase signals the gaining popularity of prescription ...
...  Glowpoint, Inc. (OTCBB: GLOW), a leading global provider of ... a leading global pharmaceutical services company has signed with ...   This new Glowpoint customer is the ... clinical, commercial, consulting and capital solutions. The firm has ...
Cached Medicine Technology:Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 2Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 3Global Pharmaceutical Services Company Turns to Glowpoint's OpenVideo™ Cloud 2
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
... microplate washers available to handle ... cell-based assays. Embla 384 Cell ... have been optimized to avoid ... robotic compatible and have been ...
ELISA Microplate Washer, Manual...
Medicine Products: